Equine Tetanus and Botulism

Equine tetanus and botulism are two distinct, life-threatening neurological diseases caused by potent neurotoxins produced by Clostridium tetani and Clostridium botulinum, respectively. Tetanus is characterized by spastic paralysis and hyperesthesia due to the action of tetanospasmin on inhibitory interneurons, while botulism presents as a flaccid paralysis resulting from botulinum toxin blocking acetylcholine release at the neuromuscular junction. Both diseases are of paramount importance in equine medicine due to their high mortality rates, zoonotic potential (botulism), and the need for rapid diagnosis and intensive care. Tetanus is often associated with contaminated wounds, especially puncture wounds of the hoof or deep lacerations, whereas botulism is typically acquired through ingestion of preformed toxin in contaminated feed (e.g., silage, haylage) or, in foals, through toxicoinfectious forms (shaker foal syndrome). The diseases affect horses of all breeds and ages, with botulism being particularly prevalent in certain geographic regions (e.g., Kentucky, Mid-Atlantic states) and during specific seasons. In the equine industry, these diseases can cause significant economic losses due to mortality, treatment costs, and loss of athletic performance. Prompt recognition, aggressive supportive care, and administration of specific antitoxins are critical for survival. This entry provides an encyclopedic overview of the etiology, epidemiology, pathophysiology, clinical signs, diagnostic approach, treatment, and prognosis for equine tetanus and botulism, based on current veterinary literature and expert consensus.

Tetanus is caused by Clostridium tetani, a Gram-positive, strictly anaerobic, spore-forming bacillus ubiquitous in soil and the gastrointestinal tract of mammals. The organism produces two exotoxins: tetanolysin, which causes local tissue necrosis, and tetanospasmin, a highly potent neurotoxin responsible for the clinical signs. Tetanospasmin binds to gangliosides at the neuromuscular junction, undergoes retrograde axonal transport to the central nervous system, and irreversibly blocks the release of inhibitory neurotransmitters (GABA and glycine) from Renshaw cells in the spinal cord and brainstem, leading to unopposed muscle contraction and spastic paralysis. Botulism is caused by Clostridium botulinum, a Gram-positive, strictly anaerobic, spore-forming bacillus that produces botulinum neurotoxin (BoNT), the most potent biological toxin known. There are seven serotypes (A-G), with types A, B, C, and E most commonly affecting horses. The toxin is a zinc-dependent endopeptidase that cleaves SNARE proteins (e.g., SNAP-25, synaptobrevin) at the neuromuscular junction, preventing acetylcholine release and causing flaccid paralysis. Botulism in horses occurs through three main routes: (1) toxicoinfectious (most common in foals, 'shaker foal syndrome'), where spores germinate in the gastrointestinal tract and produce toxin in vivo; (2) foodborne, through ingestion of preformed toxin in contaminated feed (e.g., haylage, silage, improperly fermented feed); and (3) wound botulism, rare in horses, where toxin is produced in contaminated wounds. Both diseases are non-contagious but can affect multiple animals if a common feed source is contaminated.

Tetanus is a sporadic disease with a worldwide distribution, but it is more common in regions with warm, moist climates and where soil is rich in organic matter. Horses are among the most susceptible domestic animals, with a case fatality rate of 50-80% even with treatment. There is no breed, age, or sex predisposition, but the disease is more frequently seen in horses with inadequate vaccination history. Tetanus can occur at any time of year but may be more common during the spring and summer when horses are more likely to sustain wounds. Botulism also has a worldwide distribution, but the incidence varies geographically. In North America, botulism type B is most common in the Mid-Atlantic and Kentucky regions, while type A is more prevalent in the western United States. Type C is associated with carrion contamination of feed. Botulism can affect horses of all ages, but the toxicoinfectious form (shaker foal syndrome) is most common in foals between 2 and 8 weeks of age. Outbreaks of foodborne botulism are often associated with contaminated haylage or silage, particularly when the feed has been improperly fermented or has undergone anaerobic decomposition. The disease can affect multiple horses on a farm, with morbidity rates varying depending on the level of contamination. Mortality rates are high, often exceeding 90% in untreated cases, but can be reduced with early antitoxin administration and intensive nursing care. Both diseases have significant economic impacts due to mortality, treatment costs, and loss of performance.

Tetanus: The pathogenesis of tetanus begins with contamination of a wound with C. tetani spores. In the presence of necrotic tissue and anaerobic conditions, spores germinate into vegetative bacteria that produce tetanospasmin. The toxin binds to presynaptic terminals at the neuromuscular junction, is internalized, and undergoes retrograde axonal transport to the central nervous system. Once in the spinal cord and brainstem, the toxin cleaves synaptobrevin, a SNARE protein essential for vesicle fusion, thereby blocking the release of inhibitory neurotransmitters (GABA and glycine) from Renshaw cells. This results in unopposed excitatory input to motor neurons, leading to sustained muscle contraction (spastic paralysis). The toxin also affects the autonomic nervous system, causing sympathetic overactivity (e.g., tachycardia, sweating, hypertension). The incubation period is typically 1-3 weeks but can range from days to months. Botulism: The pathogenesis of botulism involves the absorption of botulinum toxin from the gastrointestinal tract (foodborne or toxicoinfectious) or from a wound. The toxin enters the bloodstream and reaches the neuromuscular junction, where it binds to presynaptic receptors and is internalized. The light chain of the toxin cleaves SNARE proteins (e.g., SNAP-25, synaptobrevin), preventing the fusion of acetylcholine-containing vesicles with the presynaptic membrane. This blocks the release of acetylcholine, resulting in flaccid paralysis of skeletal muscles. The paralysis typically begins with the cranial nerves (e.g., dysphagia, weakness of the tongue and jaw) and progresses caudally to involve the limbs and respiratory muscles. In foals with toxicoinfectious botulism, spores ingested from the environment germinate in the gastrointestinal tract, and the toxin is produced in vivo, leading to a similar clinical syndrome. The onset of clinical signs in foodborne botulism is usually 12-24 hours after ingestion of contaminated feed, but can be longer depending on the dose.

Tetanus: The primary predisposing factor is the presence of a wound contaminated with soil, feces, or foreign material, especially deep puncture wounds (e.g., hoof nails, wire cuts) that create anaerobic conditions. Poor vaccination history is a major risk factor, as horses that have not received tetanus toxoid or have not been boostered within the past year are highly susceptible. Other factors include poor wound care, delayed veterinary attention, and environmental conditions that promote spore survival (e.g., moist, warm soil). Botulism: Predisposing factors for botulism include feeding of improperly fermented forages (haylage, silage) or contaminated feed (e.g., carcass contamination), which can contain preformed toxin. In foals, the toxicoinfectious form is more common in areas with high soil contamination and is associated with factors that promote spore germination in the gastrointestinal tract, such as a change in diet, stress, or concurrent illness. Poor hygiene in foaling areas and inadequate colostrum intake may also increase the risk. Additionally, horses that are fed round bale silage or haylage are at higher risk for foodborne botulism, especially if the bales are damaged or have been stored improperly.

Tetanus: The clinical signs of tetanus typically develop 1-3 weeks after wound contamination. Early signs include stiffness, reluctance to move, and mild muscle tremors. As the disease progresses, the classic signs of spastic paralysis become apparent: (1) Hyperesthesia and exaggerated response to sudden noise, touch, or light; (2) Prolapse of the third eyelid (nictitating membrane) due to spasm of the retractor bulbi muscle; (3) Stiff, stilted gait with a 'sawhorse' stance; (4) Trismus (lockjaw) due to masseter muscle spasm, leading to difficulty eating and drinking; (5) Dysphagia and drooling; (6) Sweating and elevated body temperature; (7) Tachycardia and tachypnea; (8) In severe cases, respiratory failure due to spasm of the respiratory muscles. The horse remains alert and conscious throughout. Botulism: The clinical signs of botulism are characterized by flaccid paralysis. In adult horses, the onset is often acute, with signs developing within 12-24 hours after ingestion of toxin. Early signs include dysphagia (difficulty swallowing), drooling, and weakness of the tongue (the horse may be unable to retract the tongue when pulled out). As the disease progresses, muscle weakness becomes generalized, leading to a staggering gait, muscle tremors, and recumbency. The horse may have a weak tail tone and decreased anal tone. Respiratory paralysis is the ultimate cause of death. In foals with shaker foal syndrome, the clinical signs are similar but may be more subtle initially, including muscle tremors, weakness, and difficulty nursing. The foal may appear 'shaky' and may have a weak suckle reflex. The disease progresses rapidly to recumbency and respiratory failure.

Tetanus: Differential diagnoses include: (1) Botulism – distinguished by flaccid paralysis, dysphagia, and lack of hyperesthesia; (2) Equine motor neuron disease (EMND) – chronic, progressive weakness and muscle atrophy; (3) Hepatic encephalopathy – depression, head pressing, and icterus; (4) Meningitis – fever, neck stiffness, and severe depression; (5) Strychnine poisoning – similar spastic paralysis but with a history of exposure; (6) Hypocalcemia (eclampsia) – muscle tremors and stiffness, but usually in lactating mares; (7) Polysaccharide storage myopathy (PSSM) – exercise-induced muscle stiffness and pain; (8) Exertional rhabdomyolysis – muscle stiffness and pain after exercise. Botulism: Differential diagnoses include: (1) Tetanus – distinguished by spastic paralysis and hyperesthesia; (2) Equine protozoal myeloencephalitis (EPM) – asymmetric ataxia and muscle atrophy; (3) Cervical vertebral stenotic myelopathy (CVSM) – ataxia and weakness, but usually with a history of progressive signs; (4) Equine herpesvirus myeloencephalopathy (EHM) – acute ataxia and urinary incontinence; (5) Grass sickness (equine dysautonomia) – dysphagia, colic, and muscle tremors; (6) Lead poisoning – dysphagia and laryngeal paralysis; (7) Tick paralysis – ascending flaccid paralysis; (8) Myasthenia gravis – rare, but causes weakness and dysphagia.

Tetanus: The diagnosis of tetanus is primarily based on clinical signs and a history of a wound or inadequate vaccination. There is no definitive antemortem test. The diagnostic algorithm includes: (1) Thorough physical examination, with emphasis on neurological assessment (e.g., third eyelid prolapse, trismus, hyperesthesia); (2) History of wound or vaccination status; (3) Wound inspection and culture (C. tetani can be cultured, but it is not always successful); (4) Rule out other causes of spastic paralysis (e.g., strychnine poisoning, hypocalcemia) through history and laboratory tests (e.g., serum calcium, magnesium). Botulism: The diagnosis of botulism is based on clinical signs, history of exposure to contaminated feed, and laboratory confirmation. The diagnostic algorithm includes: (1) Clinical examination – flaccid paralysis, dysphagia, tongue weakness; (2) History of feeding haylage/silage or recent feed changes; (3) Mouse bioassay or ELISA for botulinum toxin in serum, feces, or feed samples; (4) Culture of C. botulinum from feces or gastrointestinal contents (especially in foals); (5) Electromyography (EMG) – may show decremental response to repetitive nerve stimulation; (6) Rule out other causes of flaccid paralysis (e.g., EPM, EHM, grass sickness) through CSF analysis, serology, and other tests.

Tetanus: There are no specific laboratory abnormalities in tetanus. Routine hematology and biochemistry are usually within normal limits, although muscle enzyme (CK, AST) elevations may be seen due to muscle spasms. Blood gas analysis may reveal respiratory acidosis in severe cases due to hypoventilation. Botulism: Laboratory findings are also non-specific. In foodborne botulism, the toxin can be detected in serum, feces, or feed samples using the mouse bioassay or ELISA. In foals with toxicoinfectious botulism, C. botulinum may be cultured from feces. Hematology and biochemistry are usually unremarkable, but dehydration and electrolyte imbalances may be present due to dysphagia. In severe cases, respiratory acidosis may be present.

Tetanus: Imaging is not typically used for diagnosis, but radiography may be helpful to identify foreign bodies or fractures in wounds. Botulism: Imaging is not typically used for diagnosis, but thoracic radiography may be performed to assess for aspiration pneumonia due to dysphagia. Ultrasonography may be used to evaluate esophageal motility or to rule out other causes of dysphagia.

Tetanus: Histopathology of the central nervous system is usually unremarkable, as the toxin does not cause visible lesions. Botulism: Histopathology of the neuromuscular junction may show no significant changes. In chronic cases, muscle atrophy may be evident. Cytology of cerebrospinal fluid is normal in both diseases, which helps rule out inflammatory conditions.

Tetanus: The treatment of tetanus involves: (1) Wound debridement and cleaning to remove necrotic tissue and spores; (2) Administration of tetanus antitoxin (1500-3000 IU IV or IM) to neutralize circulating toxin; (3) Antibiotic therapy with penicillin G (22,000 IU/kg IV q6h) or metronidazole (15-25 mg/kg PO q8h) to eliminate vegetative bacteria; (4) Muscle relaxants and sedatives, such as acepromazine (0.02-0.05 mg/kg IV or IM q6-8h), phenobarbital (2-5 mg/kg IV or PO q12h), or methocarbamol (20-40 mg/kg IV or PO q8h); (5) Supportive care, including fluid therapy, nutritional support (e.g., nasogastric tube feeding or parenteral nutrition), and nursing care in a dark, quiet environment; (6) Respiratory support if needed (e.g., oxygen therapy, mechanical ventilation in severe cases). Botulism: The treatment of botulism involves: (1) Administration of botulinum antitoxin (type-specific or polyvalent) as early as possible; (2) Supportive care, including fluid therapy, nutritional support (e.g., nasogastric tube feeding), and nursing care; (3) Antibiotics are not effective against the toxin but may be used to treat secondary infections (e.g., aspiration pneumonia); (4) In foals with toxicoinfectious botulism, oral metronidazole (15-25 mg/kg PO q8h) may be used to reduce intestinal C. botulinum; (5) Respiratory support, including oxygen therapy and mechanical ventilation if necessary; (6) In severe cases, intensive care in a referral hospital is essential.

Tetanus: The prognosis for tetanus is guarded to poor, with a mortality rate of 50-80% even with intensive treatment. Factors associated with a better prognosis include early treatment, mild clinical signs, and absence of respiratory complications. Horses that survive the acute phase may take weeks to months to fully recover. Botulism: The prognosis for botulism is also guarded to poor, with a mortality rate of 90% or higher in untreated cases. With early antitoxin administration and intensive supportive care, the survival rate can be improved to 50-80%. The prognosis is better for adult horses with foodborne botulism than for foals with shaker foal syndrome. Recovery can be prolonged, and some horses may have residual weakness.

Tetanus: Follow-up care includes: (1) Monitoring for complications such as aspiration pneumonia, decubital ulcers, and muscle atrophy; (2) Gradual reintroduction of feed and water as the horse's ability to swallow improves; (3) Physical therapy to prevent muscle contractures; (4) Vaccination with tetanus toxoid after recovery to ensure long-term immunity. Botulism: Follow-up care includes: (1) Monitoring for complications such as aspiration pneumonia and decubital ulcers; (2) Gradual reintroduction of feed and water; (3) Physical therapy to aid in muscle recovery; (4) In foals, ensure adequate nutrition and monitor for secondary infections; (5) For foodborne botulism, identify and remove the contaminated feed source to prevent further cases.

Tetanus: Pearls: (1) Always consider tetanus in any horse with a wound and stiffness; (2) Prolapse of the third eyelid is a classic early sign; (3) Tetanus antitoxin is most effective when given early; (4) Provide a quiet, dark environment to minimize stimulation. Pitfalls: (1) Delaying antitoxin administration; (2) Inadequate wound debridement; (3) Overlooking the need for respiratory support; (4) Using sedatives that may cause respiratory depression. Botulism: Pearls: (1) Dysphagia and tongue weakness are early signs; (2) Always ask about feed history, especially haylage/silage; (3) Antitoxin is most effective when given early; (4) In foals, consider shaker foal syndrome if there is muscle tremors and weakness. Pitfalls: (1) Misdiagnosing as colic or other neurological diseases; (2) Delaying antitoxin administration; (3) Failing to remove contaminated feed; (4) Inadequate supportive care, especially respiratory support.

Tetanus: (1) Tetanus antitoxin: 1500-3000 IU IV or IM, once; (2) Penicillin G: 22,000 IU/kg IV q6h for 7-10 days; (3) Metronidazole: 15-25 mg/kg PO q8h for 7-10 days; (4) Acepromazine: 0.02-0.05 mg/kg IV or IM q6-8h as needed; (5) Phenobarbital: 2-5 mg/kg IV or PO q12h; (6) Methocarbamol: 20-40 mg/kg IV or PO q8h; (7) Fluid therapy: balanced polyionic fluids (e.g., lactated Ringer's solution) at maintenance (50 ml/kg/day) plus deficits; (8) Nutritional support: nasogastric tube feeding with a complete liquid diet (e.g., Equine Senior) or parenteral nutrition if needed. Botulism: (1) Botulinum antitoxin: type-specific or polyvalent, 100-200 ml IV, once; (2) Metronidazole: 15-25 mg/kg PO q8h for 7-10 days (in foals); (3) Fluid therapy: balanced polyionic fluids at maintenance plus deficits; (4) Nutritional support: nasogastric tube feeding or parenteral nutrition; (5) Antibiotics for secondary infections (e.g., penicillin G 22,000 IU/kg IV q6h, gentamicin 6.6 mg/kg IV q24h); (6) Respiratory support: oxygen therapy, mechanical ventilation if necessary.

Tetanus: The use of tetanus antitoxin and antibiotics is well-established based on clinical experience and experimental studies. A retrospective study by Green et al. (2002) reported a survival rate of 50% in horses with tetanus treated with antitoxin and supportive care. Another study by van Galen et al. (2008) found that early administration of antitoxin and aggressive muscle relaxant therapy improved outcomes. Botulism: The efficacy of botulinum antitoxin has been demonstrated in experimental and clinical studies. A study by Whitlock et al. (1999) reported a survival rate of 80% in adult horses with botulism treated with antitoxin and supportive care. In foals with shaker foal syndrome, a study by Wilkins et al. (2004) found that early antitoxin administration and intensive care improved survival. The use of metronidazole in foals is based on its activity against C. botulinum and is supported by clinical experience. Consensus guidelines from the ACVIM and AAEP recommend early antitoxin administration and aggressive supportive care for both diseases.